ATHA — Athira Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $13.27m
- -$23.40m
Annual cashflow statement for Athira Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20 | -54.9 | -95.6 | -118 | -96.9 |
| Depreciation | |||||
| Non-Cash Items | 2.29 | 5.12 | 10.4 | 9.42 | 10.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.45 | 6.16 | 11.9 | 6.53 | -12 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -24.1 | -43.1 | -72.5 | -101 | -97.2 |
| Capital Expenditures | -2.32 | -1.57 | -1.14 | -0.304 | -0.033 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -208 | -2.51 | 58.8 | 95.4 | 54.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -210 | -4.08 | 57.7 | 95.1 | 54.8 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 293 | 97.1 | 0.654 | 0.493 | 0.194 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 58.6 | 49.9 | -14.2 | -5.17 | -42.1 |